File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
  • Basic View
  • Metadata View
  • XML View
TitleA recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
 
AuthorsDu, L
Leung, VHC
Jiang, S
Zheng, B
 
KeywordsInfluenza A virus
H5N1
Hemagglutinin
Recombinant vaccine
Cross-protection
 
Issue Date2011
 
PublisherAkademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology
 
CitationThe 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11 [How to Cite?]
DOI: http://dx.doi.org/10.1556/EuJMI.1.2011.2.1
 
AbstractDevelopment of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
 
DescriptionPoster abstracts - Session D: Viral Infections and Vaccines
 
ISSN2062-509X
 
DOIhttp://dx.doi.org/10.1556/EuJMI.1.2011.2.1
 
DC FieldValue
dc.contributor.authorDu, L
 
dc.contributor.authorLeung, VHC
 
dc.contributor.authorJiang, S
 
dc.contributor.authorZheng, B
 
dc.date.accessioned2011-07-27T02:00:10Z
 
dc.date.available2011-07-27T02:00:10Z
 
dc.date.issued2011
 
dc.description.abstractDevelopment of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionPoster abstracts - Session D: Viral Infections and Vaccines
 
dc.description.otherThe 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11
 
dc.identifier.citationThe 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11 [How to Cite?]
DOI: http://dx.doi.org/10.1556/EuJMI.1.2011.2.1
 
dc.identifier.doihttp://dx.doi.org/10.1556/EuJMI.1.2011.2.1
 
dc.identifier.epage182
 
dc.identifier.hkuros188738
 
dc.identifier.issn2062-509X
 
dc.identifier.issue2
 
dc.identifier.openurl
 
dc.identifier.spage182
 
dc.identifier.urihttp://hdl.handle.net/10722/135939
 
dc.identifier.volume1
 
dc.languageeng
 
dc.publisherAkademiai Kiado Rt.. The Journal's web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology
 
dc.relation.ispartofEuropean Journal of Microbiology and Immunology
 
dc.subjectInfluenza A virus
 
dc.subjectH5N1
 
dc.subjectHemagglutinin
 
dc.subjectRecombinant vaccine
 
dc.subjectCross-protection
 
dc.titleA recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Du, L</contributor.author>
<contributor.author>Leung, VHC</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<contributor.author>Zheng, B</contributor.author>
<date.accessioned>2011-07-27T02:00:10Z</date.accessioned>
<date.available>2011-07-27T02:00:10Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11</identifier.citation>
<identifier.issn>2062-509X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135939</identifier.uri>
<description>Poster abstracts - Session D: Viral Infections and Vaccines</description>
<description.abstract>Development of effective vaccines to prevent influenza, particularly highly pathogenic avian influenza (HPAI) caused by influenza A virus (IAV) subtype H5N1, is a challenging goal. In this study, we designed and constructed two recombinant influenza vaccine candidates by fusing hemagglutinin 1 (HA1) fragment of A/Anhui/1/2005(H5N1) to either Fc of human IgG (HA1-Fc) or foldon plus Fc (HA1-Fdc), and evaluated their immune responses and cross-protection against divergent strains of H5N1 virus. Results showed that these two recombinant vaccines induced strong immune responses in the vaccinated mice, which specifically reacted with HA1 proteins and an inactivated heterologous H5N1 virus. Both proteins were able to cross-neutralize infections by one homologous strain (clade 2.3) and four heterologous strains belonging to clades 0, 1, and 2.2 of H5N1 pseudoviruses as well as three heterologous strains (clades 0, 1, and 2.3.4) of H5N1 live virus. Importantly, immunization with these two vaccine candidates, especially HA1-Fdc, provided complete cross-clade protection against high-dose lethal challenge of different strains of H5N1 virus covering clade 0, 1, and 2.3.4 in the tested mouse model. This study suggests that the recombinant fusion proteins, particularly HA1-Fdc, could be developed into an efficacious universal H5N1 influenza vaccine, providing cross-protection against infections by divergent strains of highly pathogenic H5N1 virus.</description.abstract>
<language>eng</language>
<publisher>Akademiai Kiado Rt.. The Journal&apos;s web site is located at http://akkrt.hu/73/journals/products/medicine/european_journal_of_microbiology_and_immunology</publisher>
<relation.ispartof>European Journal of Microbiology and Immunology</relation.ispartof>
<subject>Influenza A virus</subject>
<subject>H5N1</subject>
<subject>Hemagglutinin</subject>
<subject>Recombinant vaccine</subject>
<subject>Cross-protection</subject>
<title>A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=2062-509X&amp;volume=1&amp;issue=2&amp;spage=182, abstract no. D11&amp;epage=&amp;date=2011&amp;atitle=A+recombinant+vaccine+of+H5N1+HA1+fused+with+foldon+and+human+IgG+Fc+induced+complete+cross-clade+protection+against+divergent+H5N1+viruses</identifier.openurl>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1556/EuJMI.1.2011.2.1</identifier.doi>
<identifier.hkuros>188738</identifier.hkuros>
<identifier.volume>1</identifier.volume>
<identifier.issue>2</identifier.issue>
<identifier.spage>182</identifier.spage>
<identifier.epage>182</identifier.epage>
<description.other>The 1st European Conference of Microbiology and Immunology, Budapest, Hungary, 12-14 May 2011. In European Journal of Microbiology and Immunology, 2011, v. 1 n. 2, p. 182, abstract no. D11</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/135939/1/re01.htm</bitstream.url>
</item>